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Group A, B, and D, 200 µg for Group C) and were monitored for 
144 hours (Group A, B, and C) or 72 hours (Group D). PK samples 
were analyzed by liquid chromatography coupled to tandem mass 
spectrometry. PK parameters of selexipag and ACT-333679 were 
explored using ratios of geometric means and their 90% CIs.
Results: PK results (geometric mean (95% CI)) are presented in the 
table below:
The free fraction of both compounds in plasma increased only in 
Group B (30%). Group C PK data are not included here (2 subjects 
only). Selexipag 400 µg was generally well tolerated in all groups. 
Ten subjects reported 14 adverse events: 4, 6, 2, and 2 in Group 
A, B, C, and D, respectively. One serious adverse event (hepatic 
encephalopathy) occurred in Group C, in the context of urinary 
infection and previous history of encephalopathy. No clinically 
relevant changes in clinical laboratory variables and electrocardio-
grams were observed.
Conclusion: Selexipag exposure increased in subjects with mild or 
moderate liver impairment compared with healthy subjects whereas 
exposure to ACT-333679 remained unchanged in subjects with mild 
liver impairment and doubled in subjects with moderate liver impair-
ment. No conclusion could be drawn for severe liver impairment.
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Introduction: Azole antifungal drugs display a nonlinear pharma-
cokinetic profile and present pharmacokinetics/pharmacodynamic 
relationships that is the reason why therapeutic drug monitoring is 
highly recommended. In time, we observed that cystic fibrosis lung 
transplant patients show an extensive metabolism and that dose esca-
lation, without reducing time between dose intervals, cannot lead to 
reach optimal blood level. The objective of this work is to evaluate 
the administration of voriconazole 3 times daily to reach the thera-
peutic range (1–4.5 mg/L) in this population.
Patients (or Materials) and Methods: A retrospective study was car-
ried out on cystic fibrosis lung transplant patients. Inclusion criteria 
were as follow: intravenous administration of voriconazole twice 
daily with a trough concentration < 0.5 mg/L, and then dose adjust-
ment from twice to 3 times daily. Trough concentration was com-
pared before and after dose adjustment. A validated high-pressure 
liquid-chromatography tandem mass spectrometry assay was used 
to determine voriconazole concentrations
Results: Seven cystic fibrosis patients have been included (4 males, 
3 females)
After dose adjustment from twice to 3 times daily, trough con-
centrations for 6 patients were in the therapeutic range. Only 1 was 
under 1 mg/L.
Conclusion: In this population of patients, recommended twice daily 
dose of 6 mg/kg for the first 24 hours followed by 4 mg/kg cannot 
lead to trough concentration of 1 mg/L. This adjustment from twice 
daily to 3 times daily could be a good method to reach the thera-
peutic range. Nonetheless, more studies should be planed concern-
ing efficacy and tolerance. These data illustrate also the nonlinear 
pharmacokinetic of voriconazole: from 6.5 mg/kg × 2 per day to 7.4 
mg/kg × 3 per day, trough concentrations display a 10-fold increase.
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Introduction: Psoriasis is a common chronic inflammatory skin dis-
ease, which has long been recognized to be associated with depression, 
among other comorbidities. Venlafaxine (VLX), a racemic mixture 
of (S)-(+) and (R)-(-) enantiomers indicated for the treatment of 
depressive illness, is metabolized to O-desmethylvenlafaxine (ODV), 
N-desmethylvenlafaxine (NDV) and N,O-didesmethylvenlafaxine 
(NODV). Considering that inflammatory disease states have been 
associated with down-regulation of drug-metabolizing enzymes 
and transporters in the liver and considering that in psoriasis many 
CYP in skin are induced, the present study evaluates the influence 
of psoriasis on kinetic disposition and metabolism of venlafaxine 
enantiomers.
Patients (or Materials) and Methods: Patients with psoriasis (n = 
12) and healthy volunteers (n = 11) were treated with a single oral 
dose of racemic venlafaxine (150 mg). Serial blood samples were col-
lected up to 48 hours after drug administration. Venlafaxine and its 
metabolites enantiomers were analyzed in plasma samples by LC-MS/
MS coupled with a chiral column Chirobiotic V. Pharmacokinetics 
parameters were evaluated using the WinNonlin software.
Results: Compared with healthy subjects who were similar overall in 
terms of age, sex, and body mass index (BMI), the means area under 
the plasma concentration-time curve from time zero extrapolated to 
infinity (AUC0-∞) for venlafaxine and its metabolites enantiomers did 
not differ (unpaired t test) in patients with psoriasis. The following 
Group A Group B Group D
Parameter Selexipag ACT-333679 Selexipag ACT-333679 Selexipag ACT-333679
Cmax1 
[ng/mL]
3.9 (2.8–
5.3)
4.5 (3.1–
6.7)
5.4 (3.9–
7.3)
5.3 (4.6–
6.0)
1.9 (1.5–
2.4)
3.8 (3.0–
5.0)
tmax2 [h] 1.0 (1.0–
4.0)
5.0 (3.0–
6.0)
2.0 (1.0–
6.0)
6.0 (4.0–
7.0)
1.0 (1.0–
2.0)
4.0 (4.0–
6.0)
t1/23 [h] 1.6 (1.3–
2.1)
6.5 (4.9–
8.6)
2.2 (1.6–
3.0)
15.9 
(10.1–
25.0)
1.1 (0.8–
1.4)
12.6 (9.1–
17.5)
AUC0-∞4 
[ng*h/
mL]
10.9 
(8.6–
13.8)
29.6 
(20.6–
42.6)
23.5 
(17.0–
32.4)
56.1 
(42.8–
73.5)
5.3 (4.5–
6.2)
25.3 
(21.9–
29.3)
1peak concentration; 2time to reach Cmax, median (range); 3terminal half-life, 4expo-
sure from 0 to ∞.
n 7
age (years) 24.7 (5.44) [21–32]
weight (kg) 48,8 ± 4,95 [44–56)]
time posttransplant (days) 22,8 ± 27,13 [8.5–83.5]
Before dose adjustment After dose adjustment
Trough concentration (mg/L) 0.25 (0.15) [0.03–0.52] 2.26 (1.10) [0.68–4]
Voriconazole dose (mg/kg) 6,47±2,12 [4–9.2 ) × 2/d 7.35 (1.52) [5.36–9,17] × 3/d
